The award recognizes CDRD’s contributions and impact as Canada’s national life sciences venture, bringing together national and international partners to be a catalyst for Canadian life sciences leading the world; and powering the country’s industry by creating and growing companies of scale while training the scientific business talent needed to drive them to become leading global anchors for Canada.
Sepset Biosciences is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis.
Vancouver, Canada: CDRD – The Centre for Drug Research and Development, Canada’s national life sciences venture, is pleased to announce the first cohort of the CDRD Academy’s Executive Institute. Earlier…
Dr. Peter Bergqvist describes how some of his work contributed to a recent commercial outcome for TxCell (now Sangamo Therapeutics) with our academic partner Dr. Megan Levings at UBC. The…
CDRD will provide a portfolio of targeted antibodies and Schrödinger will apply its advanced computation platform in order to prioritize these drug candidates and otherwise accelerate discovery. The initial project will involve an immune checkpoint target that is present on cancer stem cells.
As an Entrepreneur-in-Residence, Sacha Mann will work with CDRD leadership to identify specific areas of strategic commercial opportunity, and then in partnership with other stakeholders, drive the building of a new company of scale that can develop those opportunities, and grow into a strong new anchor for Canada’s life science sector. Sacha has a unique breadth of experience in life sciences companies. Sacha has been a life sciences investor, company innovator, and leader, and she has managed the entire commercialization cycle from spinning technology out of academia, raising venture capital financing, in-licensing assets into emerging companies, and partnering with global players. She has worked and invested across Canada and globally, most recently as CEO and Director of Biosys UK Ltd., a venture-backed, clinical stage microbiome company headquartered in London.
As an Entrepreneur-in-Residence, Dr. Janes will work with CDRD leadership to identify specific areas of strategic commercial opportunity, and then in partnership with other stakeholders, drive the building of a new company of scale that can develop those opportunities, and grow into a strong new anchor for Canada’s life science sector.
CDRD and Pfizer Canada today announced the launch of the CDRD Executive Institute under the umbrella of The CDRD Academy. The Institute, made possible by a significant $1,000,000 contribution by Pfizer Canada, aims to provide ongoing executive development to ensure that the Canadian life sciences sector has the management talent it needs to lead the world.